CD274 and neoplasm: In patients with PD-L1 immune cell-positive tumours (≥ 1% PD-L1 expression), median OS was 25.4 months with atezolizumab vs 17.9 months with placebo; the HR was 0.67 but statistical significance was not formally tested as per the prespecified testing hierarchy.